Evoke Pharma Balance Sheet Health

Financial Health criteria checks 2/6

Evoke Pharma has a total shareholder equity of $-2.6M and total debt of $5.0M, which brings its debt-to-equity ratio to -193.8%. Its total assets and total liabilities are $7.1M and $9.6M respectively.

Key information

-193.8%

Debt to equity ratio

US$5.00m

Debt

Interest coverage ration/a
CashUS$4.74m
Equity-US$2.58m
Total liabilitiesUS$9.65m
Total assetsUS$7.07m

Recent financial health updates

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Jan 22
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Recent updates

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Jan 22
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Evoke to get US patent for nasal spray Gimoti

Sep 20

Evoke Pharma Q2 GAAP loss per share narrows, revenue up

Aug 10

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Jul 06

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Oct 22
Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Jul 06
Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Evoke Pharma announces positive findings from second GIMOTI market research study

Jun 15

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book

Jun 08

Evoke Pharma issued new U.S. patent covering methods of use for Gimoti

Jun 02

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Mar 14
Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Evoke Pharma shares surge on positive findings from Gimoti market research study

Jan 13

Evoke Pharma EPS beats by $0.02

Nov 10

Financial Position Analysis

Short Term Liabilities: EVOK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: EVOK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: EVOK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: EVOK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EVOK has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: EVOK is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.